Filing Flows › Verrica Pharmaceuticals (VRCA) › Q1 2025
Verrica Pharmaceuticals (VRCA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Verrica Pharmaceuticals (VRCA) reported revenue of $3.4M for the first quarter 2025 (Q1 2025), -10% from a year earlier and +900% from the quarter before. Operating margin was -236.4%, net loss $9.7M (283.3% of revenue).
Verrica Pharmaceuticals, Q1 2025: revenue $3.4M (-10% year over year), operating margin -236.4%, net loss $9.7M, operating cash flow −$12.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.4M | +900% | -10% |
| Operating profit | −$8.1M | — | — |
| Net earnings | −$9.7M | — | — |
| Operating cash flow | −$12.7M | — | — |
What changed
Revenue was $3.4M in Q1 2025, down 10% year over year and up 900% from the previous quarter. Product was the largest line at 100% of revenue. Collaboration lost $577K year over year (down 97%), 149% of the total change.
Operating costs exceeded revenue by $8.1M, an operating margin of -236.4%. Total costs fell 48% while revenue fell 10%. The quarter ended with a net loss of $9.7M, narrower than the previous quarter's $16.2M loss.
Operating cash flow was −$12.7M. Non-cash charges added back $52K of depreciation and $1.0M of share-based compensation. Working capital and other items used $4.0M.
Questions
What was Verrica Pharmaceuticals' revenue in the first quarter 2025?
Verrica Pharmaceuticals (VRCA) reported revenue of $3.4M for the first quarter 2025 (Q1 2025), -10% from a year earlier and +900% from the quarter before.
Was Verrica Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $8.1M (-236.4% of revenue) and net loss $9.7M.